A Vella

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. Vella A. Does caloric restriction alone explain the effects of Roux-en-Y gastric bypass on glucose metabolism? Not by a long limb. Diabetes. 2013;62:3017-8 pubmed publisher
  2. Vella A, Jensen M, Nair K. Eulogy for the Metabolic Clinical Investigator?. Diabetes. 2016;65:2821-3 pubmed publisher
  3. Vella A, MATVEYENKO A. Walking a fine line between ?-cell secretion and proliferation. J Biol Chem. 2018;293:14190-14191 pubmed publisher
    ..This in turn might open up new avenues to the restoration of insulin secretion in people with type 2 diabetes. ..
  4. MATVEYENKO A, Vella A. Regenerative medicine in diabetes. Mayo Clin Proc. 2015;90:546-54 pubmed publisher
    ..Efforts to date intended to capitalize on current knowledge of islet cell development and stimulus-secretion coupling of the β cell are encouraging but as yet of little clinical relevance. ..
  5. Sathananthan M, Shah M, Edens K, Grothe K, Piccinini F, Farrugia L, et al. Six and 12 Weeks of Caloric Restriction Increases β Cell Function and Lowers Fasting and Postprandial Glucose Concentrations in People with Type 2 Diabetes. J Nutr. 2015;145:2046-51 pubmed publisher
    ..An additional 6 wk of caloric restriction maintained the improvement in glucose metabolism. This trial was registered at clinicaltrials.gov as NCT01094054. ..
  6. Shah M, Varghese R, Miles J, Piccinini F, Dalla Man C, Cobelli C, et al. TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes. Diabetes. 2016;65:371-80 pubmed publisher
    ..These data imply that a genetic variant harbored within the TCF7L2 locus impairs glucose tolerance through effects on glucagon as well as on insulin secretion. ..
  7. Vella A, Bock G, Giesler P, Burton D, Serra D, Saylan M, et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf). 2008;69:737-44 pubmed publisher
    ..01). Vildagliptin does not alter satiation or gastric volume in people with type 2 diabetes despite elevated GLP-1 concentrations. Compensatory changes in enteroendocrine secretion could account for the lack of gastrointestinal symptoms. ..
  8. Varghese R, Viegas I, Barosa C, Marques C, Shah M, Rizza R, et al. Diabetes-Associated Variation in TCF7L2 Is Not Associated With Hepatic or Extrahepatic Insulin Resistance. Diabetes. 2016;65:887-92 pubmed publisher
    ..These data indicate that genetic variation at TCF7L2 does not predispose an individual to type 2 diabetes by altering either hepatic or extrahepatic insulin action. ..
  9. Kittah N, Vella A. MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia. Eur J Endocrinol. 2017;177:R37-R47 pubmed publisher
    ..We provide an overview of the pathogenesis and management of hypoglycemia in these situations. ..

More Information

Publications11

  1. Sharma A, Laurenti M, Dalla Man C, Varghese R, Cobelli C, Rizza R, et al. Glucose metabolism during rotational shift-work in healthcare workers. Diabetologia. 2017;60:1483-1490 pubmed publisher
    ..As a consequence, higher postprandial glucose concentrations are observed during the night shift. ..
  2. Vella A, Camilleri M. The Gastrointestinal Tract as an Integrator of Mechanical and Hormonal Response to Nutrient Ingestion. Diabetes. 2017;66:2729-2737 pubmed publisher
    ..The overall goal of this review is to examine current knowledge of the gastrointestinal contributions to metabolic control. ..